Polyphyllin I mitigates psoriasiform inflammation and prevents relapse by modulating CLEC7A and inhibiting pyroptosis
Phytomedicine · 2026
DOI: 10.1016/j.phymed.2025.157658 ↗Kurz gefasst
Fachartikel in der Zeitschrift Phytomedicine, 2026. Verfasst von Xiangnan Zhou und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Wangjing Hospital, China Academy of Chinese Medical Sciences, Beijing, PR China; Central Laboratory, Shanghai Skin Disease…. Hauptthemen laut MEDLINE: Psoriasis, Pyroptosis, Lectins, C-Type, Diosgenin. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 77 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Psoriasis remains a significant global health concern, with a lack of effective treatments, thus driving the need for innovative therapeutic approaches. Polyphyllin I (PPI) has demonstrated potential in mitigating inflammation and controlling cellular growth, although the precise mechanisms underlying its effects and its full therapeutic capabilities in psoriasis require further investigation. PURPOSE: To assess the efficacy of PPI and examine its role in treating psoriasis and preventing relapse. METHODS: We designed both animal and cell-based experiments to investigate the efficacy and anti-inflammatory effects of PPI in treating psoriasis and preventing disease recurrence. To elucidate the potential mechanisms underlying PPI's therapeutic effects in psoriasis, we employed an integrative multi-omics approach combining bulk RNA sequencing (RNA-seq), single-cell RNA sequencing (scRNA-seq), and spatial transcriptomics (ST) analysis. RESULTS: PPI inhibited abnormal keratinocyte proliferation, regulating the cell cycle and pyroptosis. In murine models of psoriasis and its relapse, PPI notably reduced symptoms such as erythema, scaling, epidermal thickening, and elevated inflammatory markers, including interleukin (IL)-17, IL-23, and IL-6 in peripheral blood, thereby confirming its therapeutic and relapse-prevention capabilities. Bioinformatics analysis indicated that PPI modulated C-Type Lectin Domain Containing 7A (CLEC7A) and inflammatory immune signaling pathways, and highlighted CLEC7A as a potential target for psoriasis prevention and treatment. CLEC7A+ keratinocytes engaged fibroblasts via the Kallikrein (KLK) 8 - coagulation factor II thrombin receptor (F2R) pathway. PPI treatment significantly downregulated the expression of CLEC7A, KLK8, and F2R in psoriasis mice. Notably, the combination of siRNA targeting CLEC7A (si-CLEC7A) and high-dose PPI group (PPI-H) further suppressed the expression of key inflammatory cytokines (IL-17, IL-23A, IL-6), proteases (KLK8, F2R), and pyroptosis-associated proteins (Caspase-1, GSDMD, IL-1β, and IL-18) of psoriasis. CONCLUSION: PPI may exert therapeutic potential in treating psoriasis and preventing disease recurrence by downregulating the CLEC7A/KLK8/F2R signaling axis, thereby attenuating inflammatory responses and pyroptosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Wangjing Hospital, China Academy of Chinese Medical Sciences, Beijing, PR China; Central Laboratory, Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai, PR China.
- Central Laboratory, Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai, PR China.
- Department of Urology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences. Graduate School of Peking Union Medical College, Chinese Academy of Medical…
- Department of Dermatology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, PR China.
- Diagnostic Center of Infections, The Second Hospital of Hebei Medical university, Shijiazhuang, PR China. Electronic address: lijihong@hb2h.com.
- State Key Laboratory of Medical Molecular Biology & Department of Medical Genetics, Institute of Basic Medical Sciences & School of Basic Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Bei…
Zitieren
APA
Zhou, X., Chen, Q., Chen, Z., Song, B., Li, J., & Ning, J. (2026). Polyphyllin I mitigates psoriasiform inflammation and prevents relapse by modulating CLEC7A and inhibiting pyroptosis. Phytomedicine. https://doi.org/10.1016/j.phymed.2025.157658
Vancouver
Zhou X, Chen Q, Chen Z, Song B, Li J, Ning J. Polyphyllin I mitigates psoriasiform inflammation and prevents relapse by modulating CLEC7A and inhibiting pyroptosis. Phytomedicine. 2026. doi:10.1016/j.phymed.2025.157658
BibTeX
@article{Zhou2026,
author = {Zhou, Xiangnan and Chen, Qilong and Chen, Ziyin and Song, Biao and Li, Jihong and Ning, Jingyuan},
title = {Polyphyllin I mitigates psoriasiform inflammation and prevents relapse by modulating CLEC7A and inhibiting pyroptosis},
journal = {Phytomedicine},
year = {2026},
doi = {10.1016/j.phymed.2025.157658}
}
EUVIMED